Janssen, J&J Pay Millions to Settle Risperdal Off-Label Promotion Allegations

WASHINGTON, D.C. — Janssen Pharmaceuticals Inc. and its parent, Johnson & Johnson, (NYSE: J&J) have agreed to pay $485 million in criminal fines and a $1.72 million civil settlement to settle charges that they illegally marketed Risperdal for off-label uses and paid kickbacks to a nursing home pharmacy.

Under an Oct. 29 plea agreement, JPI agreed to pay $400 million, of which $334 million will be applied as a criminal fine and $66 million will be applied as substitute assets to satisfy the company’s forfeiture obligation. Under a separate agreement finalized Nov. 4, the companies agreed to pay $1,253,024 to …